ジャーナル・オブ・オンコロジーの研究と治療

抽象的な

The Action of Statins on Prostate Cancer: A Clinical Overview

Panagiotis Boutsikos, Nikolaos Dimitriadis, Michalis Karamanis, Dimitrios Dardas, Panayiota Christodoulou, Theodora Kyriakou, Christoforos Vellios, Anastasis Stephanou and Ioannis Patrikios

Background: Statins are one of the most commonly prescribed medicines and are known to lower the level of cholesterol in blood. High cholesterol can increase your risk of developing cardiovascular disease, which includes conditions such as coronary heart disease. This is achieved by the inhibition of the HMG-CoA reductase. Prostate cancer is the most common cancer in men and usually develops slowly, so there may be no signs for many years. Genetic contributions have been associated with prostate cancer. However, no single gene is responsible for prostate cancer. Moreover, there are also reports that link prostate cancer and the use of medications including statins implicated in decreasing prostate cancer risk.
Purpose: The aim of this study is to find the clinical correlation between statins and prostate cancer, in order to conclude if there is positive or negative impact in progression of the disease.
Methods: In the present study we collected only the related clinical trials (2010 to 2017) and we excluded the studies in which statins are not main parameter of the clinical trial.
Outcomes: The effects of statins in prostate cancer, according to previous clinical trials, are not well defined. Evidence suggesting a protective role of statins against prostate cancer are well documented. However, other reports indicate no association with statin medication and prostate cancer progression.